• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Shareholders accuse St. Jude Medical of hiding Riata problems

Shareholders accuse St. Jude Medical of hiding Riata problems

June 15, 2012 By MassDevice staff

St. Jude Medical logo

St. Jude Medical (NYSE:STJ) shareholders filed a lawsuit this week accusing the company and its CEO of down-playing device failures that led to the recall of a set of defibrillator leads in a "scheme" to artificially inflate the company’s share price.

The lawsuit accuses the company of concealing problems with its Riata and QuickFlex line of leads, which were both recalled in the last 6 months.

St. Jude recalled its Riata defibrillator leads in December over concerns that the electrical wires could poke through their insulated coating and protrude into the body.

Reports later emerged that the devices may also be prone to internal short circuits that were more rare than the exposed wires but potentially more dangerous.

Shareholders accused St. Jude of hiding the electrical problem and down-playing the risk of Riata lead failure, noting that Starks told investors during a conference call that the company has "the most robust post-market surveillance of lead reliability of anybody in the industry. … So we have a lot of confidence that we have a good handle on St. Jude Medical device reliability."

A few months into the Riata recall, St. Jude also pulled its QuickSite and QuickFlex left-ventricular leads after finding 39 confirmed cases of exposed wires.

"The wire protrusions from the QuickSite and QuickFlex left-ventricular leads were apparent to Starks since they utilized the same silicone coating that malfunctioned in the Riata leads," according to the complaint.

The lawsuit further noted the latest news of exposed conductors reported in a single Durata lead, the company’s next-generation defibrillator lead that touts a more durable coating that the silicone used in the Riata, QuickSite and QuickFlex leads.

St. Jude has attempted to distance its Durata leads from the Riata recall foofaraw with reports and presentations highlighting the differences between the leads. Some Wall Street analysts cast a skeptical eye on the latest Durata lead exposure report, given that the report lacked important identifying characteristics. Nonetheless, the news sent STJ shares tumbling 6% when the issue was reported Tuesday.

Noted cardiologist Dr. Robert Hauser, who was responsible for the highly controversial study linking the Riata leads to internal short circuits, backed the validity of the Durata report but warned that The Street was making too much of it, Reuters reported.

"It’s one case, so it’s concerning, but hardly definitive. It just raises the question," Hauser told the wire service. "The impact is probably going to be greater than what this case actually represents."

Filed Under: Legal News, News Well, Recalls, Wall Street Beat Tagged With: Cardiac Rhythm Management, stjudemedical

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy